Read our response to the launch of the industrial strategy.

On 23 January 2017, the Government published its Industrial Strategy Green Paper. The paper gave a priority to the biopharmaceutical industry in recognition of its contribution to the UK economy.

On 30 August 2017, the Life Sciences Industrial Strategy was published. Life sciences is the first sector to publish an industrial strategy which shows its importance to the future of the UK's economic success.

The Life Sciences Industrial Strategy includes recommendations on how the Government might exploit the UK's existing strength in life sciences to increase the pace of economic growth in this sector. Its key recommendations include:

  • Sustaining and increasing funding for basic science to match international competition
  • Ensuring the fiscal environment (including tax credits, grants, loans and capital allowances) supports growth and attracts manufacturing investment
  • Adopting the Accelerated Access Review to secure faster patient access to innovative new treatments and technologies
  • Improving the collection of health data and streamlining access
  • Developing and delivering a skills action plan, including a migration system that allows for the recruitment and retention of highly skilled workers

The ABPI was a member of the Life Sciences Industrial Strategy Board and helped to develop this Strategy.​

The pharmaceutical sector's contribution to the UK economy

PwC published a new report on Monday 6 March 2017, The economic contribution of the UK Life Science industry, to determine the value added to the UK economy by the life sciences sector. 

The pharmaceutical industry is a major contributor to the economy of the UK and brings life-saving and life-enhancing medicines to patients. The ABPI represents companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring the UK remains at the forefront of helping patients prevent, manage and overcome disease. The UK biopharmaceutical industry has:

  • Strong clusters across the country, including in the South East, North West and Scotland.
  • Over 62,000 employees
  • The highest productivity of any high technology sector (over £330,000 GVA per employee)
  • Exports worth £30bn
  • More research and development spending in the UK than any other sector (£4bn per annum)